DGAT2 and hyperlipidemia: Additionally, we observed the opposite effects of SR8278 (a known REV-ERBα antagonist27) on HFD-fed mice, including exacerbated obesity, aggravated hyperlipidemia and increased intestinal DGAT2 (Fig. 8e–h).